{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:53:20Z","timestamp":1794254000120,"version":"4.9.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,11,29]],"date-time":"2005-11-29T00:00:00Z","timestamp":1133222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s00428-005-0089-x","type":"journal-article","created":{"date-parts":[[2005,11,28]],"date-time":"2005-11-28T09:43:50Z","timestamp":1133171030000},"page":"337-343","source":"Crossref","is-referenced-by-count":84,"title":["Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement"],"prefix":"10.1007","volume":"448","author":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rapkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mones","family":"Abu-Asab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tsokos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Quezado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,11,29]]},"reference":[{"key":"89_CR1","doi-asserted-by":"crossref","unstructured":"(1984) Case 2-1984: Fabry\u2019s disease. N Engl J Med 310:1607","DOI":"10.1056\/NEJM198406143102415"},{"key":"89_CR2","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1212\/01.WNL.0000166000.24321.4F","volume":"64","author":"G Altarescu","year":"2005","unstructured":"Altarescu G, Moore DF, Schiffmann R (2005) Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 64:2148\u20132150","journal-title":"Neurology"},{"key":"89_CR3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.CIR.0000154550.15963.80","volume":"111","author":"PF Bodary","year":"2005","unstructured":"Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, Shayman JA, Eitzman DT (2005) Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 111:629\u2013632","journal-title":"Circulation"},{"key":"89_CR4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163\u20131167","journal-title":"N Engl J Med"},{"key":"89_CR5","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733\u20133774","edition":"8"},{"key":"89_CR6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/imj.1970.19.1.58","volume":"19","author":"C Duncan","year":"1970","unstructured":"Duncan C, McLeod GM (1970) Angiokeratoma corporis diffusum universale (Fabry\u2019s disease): a case with gross myocardial involvement. Australas Ann Med 19:58\u201361","journal-title":"Australas Ann Med"},{"key":"89_CR7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1651-2227.2003.tb00222.x","volume":"92","author":"M Elleder","year":"2003","unstructured":"Elleder M (2003) Sequelae of storage in Fabry disease\u2014pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 92:46\u201353; discussion 45","journal-title":"Acta Paediatr Suppl"},{"key":"89_CR8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"89_CR9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-117-3-221","volume":"117","author":"EA Fisher","year":"1992","unstructured":"Fisher EA, Desnick RJ, Gordon RE, Eng CM, Griepp R, Goldman ME (1992) Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med 117:221\u2013223","journal-title":"Ann Intern Med"},{"key":"89_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmg.20.4.309","volume":"20","author":"N Gadoth","year":"1983","unstructured":"Gadoth N, Sandbank U (1983) Involvement of dorsal root ganglia in Fabry\u2019s disease. J Med Genet 20:309\u2013312","journal-title":"J Med Genet"},{"key":"89_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1651-2227.2002.tb03105.x","volume":"91","author":"C Kampmann","year":"2002","unstructured":"Kampmann C, Wiethoff CM, Martin C, Wenzel A, Kampmann R, Whybra C, Miebach E, Beck M (2002) Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 91:21\u201327","journal-title":"Acta Paediatr Suppl"},{"key":"89_CR12","first-page":"15","volume":"14","author":"J Kotnik","year":"2005","unstructured":"Kotnik J, Kotnik F, Desnick RJ (2005) Fabry disease. A case report. Acta Dermatovenerolog Alp Panon Adriat 14:15\u201319","journal-title":"Acta Dermatovenerolog Alp Panon Adriat"},{"key":"89_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1012428009627","volume":"24","author":"A Linhart","year":"2001","unstructured":"Linhart A, Lubanda JC, Palecek T, Bultas J, Karetova D, Ledvinova J, Elleder M, Aschermann M (2001) Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24:75\u201383; discussion 65","journal-title":"J Inherit Metab Dis"},{"key":"89_CR14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","volume":"104","author":"DF Moore","year":"2001","unstructured":"Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P et al (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104:1506\u20131512","journal-title":"Circulation"},{"key":"89_CR15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/jmri.20162","volume":"20","author":"DF Moore","year":"2004","unstructured":"Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, Steiner RD, Rhead WJ, Brady RO, Hazen SL, Schiffmann R (2004) Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality\u2014an arterial spin tagging study. J Magn Reson Imaging 20:674\u2013683","journal-title":"J Magn Reson Imaging"},{"key":"89_CR16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1442-9071.2005.00990.x","volume":"33","author":"TT Nguyen","year":"2005","unstructured":"Nguyen TT, Gin T, Nicholls K, Low M, Galanos J, Crawford A (2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 33:164\u2013168","journal-title":"Clin Experiment Ophthalmol"},{"key":"89_CR17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","volume":"28","author":"R Schiffmann","year":"2003","unstructured":"Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703\u2013710","journal-title":"Muscle Nerve"},{"key":"89_CR18","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"89_CR19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1034\/j.1399-0004.2003.630107.x","volume":"63","author":"M Senechal","year":"2003","unstructured":"Senechal M, Germain DP (2003) Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients. Clin Genet 63:46\u201352","journal-title":"Clin Genet"},{"key":"89_CR20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF00697017","volume":"30","author":"T Tabira","year":"1974","unstructured":"Tabira T, Goto I, Kuroiwa Y, Kikuchi M (1974) Neuropathological and biochemical studies in Fabry\u2019s disease. Acta Neuropathol 30:345\u2013354","journal-title":"Acta Neuropathol"},{"key":"89_CR21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O\u2019Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933\u20131946","journal-title":"Kidney Int"},{"key":"89_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-005-0089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-005-0089-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-005-0089-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T06:22:56Z","timestamp":1586586176000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-005-0089-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,29]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["89"],"URL":"https:\/\/doi.org\/10.1007\/s00428-005-0089-x","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,29]]}}}